Colonic Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Colonic Disease

MalaCards integrated aliases for Colonic Disease:

Name: Colonic Disease 12 15
Colonic Diseases 54 42 43 71
Colon Disorder 12


External Ids:

Disease Ontology 12 DOID:5353
MeSH 43 D003108
SNOMED-CT 67 128524007
UMLS 71 C0009373

Summaries for Colonic Disease

MedlinePlus : 42 Your colon, also known as the large intestine, is part of your digestive system. It's a long, hollow tube at the end of your digestive tract where your body makes and stores stool. Many disorders affect the colon's ability to work properly. Some of these include Colorectal cancer Colonic polyps - extra tissue growing in the colon that can become cancerous Ulcerative colitis - ulcers of the colon and rectum Diverticulitis - inflammation or infection of pouches in the colon Irritable bowel syndrome - an uncomfortable condition causing abdominal cramping and other symptoms Treatment for colonic diseases varies greatly depending on the disease and its severity. Treatment may involve diet, medicines and in some cases, surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Colonic Disease, also known as colonic diseases, is related to colorectal cancer and ileitis, and has symptoms including nausea and vomiting, abdominal pain and constipation. An important gene associated with Colonic Disease is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Prolactin Signaling Pathway and MicroRNAs in cancer. The drugs Bisacodyl and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and kidney.

Disease Ontology : 12 A intestinal disease located in the colon.

Wikipedia : 74 The large intestine, also known as the large bowel, is the last part of the gastrointestinal tract and... more...

Related Diseases for Colonic Disease

Diseases related to Colonic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 300)
# Related Disease Score Top Affiliating Genes
1 colorectal cancer 31.0 STAT3 NOD2 MIR9-1 MIR31 MIR30A MIR21
2 ileitis 30.9 STAT3 NOD2 CCR6
3 gastrointestinal system disease 30.7 MIR9-1 MIR31 MIR30A MIR21 MIR200A MIR199A1
4 intestinal disease 30.6 NOD2 MIR9-1 MIR31 MIR30A MIR21 MIR200A
5 endometriosis 30.5 MIR200A MIR199A1 MIR145 MIR143 MIR125A ESR1
6 pancreatic adenocarcinoma 30.5 STAT3 MIR21 MIR200A MIR155 MIR145 JAK1
7 colorectal adenoma 30.5 MIR21 MIR17 APC
8 ovarian cancer 30.4 STAT3 MIR9-1 MIR31 MIR30A MIR21 MIR200A
9 pancreatic cancer 30.4 STAT3 MIR31 MIR30A MIR21 MIR200A MIR199A1
10 breast cancer 30.3 STAT3 MIR9-1 MIR31 MIR30A MIR21 MIR200A
11 cholangitis, primary sclerosing 30.1 NOD2 MIR199A1 CCR6
12 functional colonic disease 12.4
13 megacolon 11.3
14 intestinal pseudo-obstruction 11.0
15 diverticulitis of colon 11.0
16 bacterial infectious disease 10.8 NOD2 MIR155 H2AC18 CCR6
17 pre-malignant neoplasm 10.8 MIR17 MIR143 H2AC18 ESR1 CCR6
18 cervix small cell carcinoma 10.8 MIR199A1 MIR145 MIR143
19 intestinal benign neoplasm 10.8 STAT3 MIR21 MIR199A1 MIR18A MIR17 MIR145
20 esophagus adenocarcinoma 10.8 MIR21 MIR199A1 MIR145 MIR143
21 colonic benign neoplasm 10.8 STAT3 MIR18A MIR143 H2AC18 CCR6 APC
22 lymphangioma 10.8 STAT3 MIR18A MIR143 H2AC18 CCR6 APC
23 breast implant-associated anaplastic large cell lymphoma 10.8 STAT3 JAK1 CCR6
24 gastrointestinal system benign neoplasm 10.8 STAT3 MIR30A MIR21 MIR199A1 MIR18A MIR17
25 gallbladder disease 10.8 MIR199A1 MIR17 MIR145 MIR143 CCR6
26 ovarian serous carcinoma 10.8 MIR21 MIR200A MIR199A1 MIR145 MIR143 MIR125A
27 suppression of tumorigenicity 12 10.8 STAT3 MIR199A1 MIR145 H2AC18 ESR1
28 cerebral arterial disease 10.8 MIR199A1 MIR145 MIR143 MIR125A
29 pleural disease 10.8 MIR199A1 MIR17 MIR125A H2AC18 CCR6
30 lymphadenitis 10.8 STAT3 NOD2 MIR145 CCR6
31 diffuse large b-cell lymphoma 10.8 STAT3 MIR21 MIR199A1 MIR17 MIR155 MIR145
32 extrinsic cardiomyopathy 10.8 MIR21 MIR199A1 H2AC18 CCR6
33 uveal disease 10.8 NOD2 MIR9-1 MIR199A1 MIR125A H2AC18 CCR6
34 in situ carcinoma 10.8 MIR17 MIR143 H2AC18 ESR1
35 testicular disease 10.8 NOD2 MIR199A1 H2AC18 CCR6
36 leukocyte disease 10.8 STAT3 MIR30A MIR21 MIR199A1 MIR17 MIR155
37 cervix carcinoma 10.8 STAT3 MIR200A MIR199A1 MIR155 H2AC18 CCR6
38 lipid storage disease 10.8 MIR21 MIR199A1 MIR155 H2AC18 CCR6
39 infratentorial cancer 10.8 MIR9-1 MIR199A1 MIR18A MIR17 H2AC18 APC
40 hypersensitivity reaction type iv disease 10.8 NOD2 MIR155 H2AC18 CCR6
41 bronchial disease 10.8 MIR21 MIR17 MIR155 H2AC18 CCR6
42 lysosomal storage disease 10.8 MIR21 MIR199A1 MIR155 H2AC18 CTSD CCR6
43 oropharynx cancer 10.8 MIR9-1 MIR199A1 H2AC18 APC
44 cardiovascular organ benign neoplasm 10.8 MIR143 H2AC18 CCR6 APC
45 tongue disease 10.8 MIR31 MIR30A MIR21 MIR199A1 MIR18A MIR17
46 laryngeal disease 10.8 MIR9-1 MIR31 MIR21 MIR17 MIR155 MIR143
47 bile duct disease 10.8 MIR9-1 MIR30A MIR200A MIR199A1 MIR17 MIR145
48 thyroid gland disease 10.8 MIR9-1 MIR199A1 MIR17 MIR125A H2AC18 CCR6
49 primary bacterial infectious disease 10.8 NOD2 MIR21 MIR155 MIR125A H2AC18 CCR6
50 bone cancer 10.8 MIR9-1 MIR31 MIR21 MIR199A1 MIR17 MIR155

Graphical network of the top 20 diseases related to Colonic Disease:

Diseases related to Colonic Disease

Symptoms & Phenotypes for Colonic Disease

UMLS symptoms related to Colonic Disease:

nausea and vomiting, abdominal pain, constipation, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

Drugs & Therapeutics for Colonic Disease

Drugs for Colonic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Bisacodyl Approved Phase 4 603-50-9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Ramosetron Investigational Phase 4 132036-88-5
8 Fibrinolytic Agents Phase 4
9 Platelet Aggregation Inhibitors Phase 4
10 Cyclooxygenase Inhibitors Phase 4
11 Anti-Inflammatory Agents, Non-Steroidal Phase 4
12 Olive Phase 4
13 Antiemetics Phase 4
14 Micronutrients Phase 4
15 Vitamins Phase 4
16 Trace Elements Phase 4
17 Nutrients Phase 4
18 Calciferol Phase 4
19 Laxatives Phase 4
20 Cathartics Phase 4
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
Dexmedetomidine Approved, Vet_approved Phase 3 113775-47-6 5311068 68602
Peppermint oil Approved, Investigational Phase 3 8006-90-4
Peppermint Approved Phase 3
Eluxadoline Approved, Investigational Phase 3 864821-90-9
Desipramine Approved, Investigational Phase 3 50-47-5 2995
Sodium sulfate Approved, Vet_approved Phase 3 7757-82-6
leucovorin Approved Phase 3 58-05-9 6006 143
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
Bevacizumab Approved, Investigational Phase 3 216974-75-3
Budesonide Approved Phase 3 51333-22-3 63006 5281004
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
35 Visilizumab Investigational Phase 2, Phase 3 219716-33-3
36 Adrenergic alpha-Agonists Phase 3
37 Adrenergic Agonists Phase 3
38 Parasympatholytics Phase 3
39 Adrenergic Agents Phase 3
40 Anti-Bacterial Agents Phase 3
41 Immunologic Factors Phase 2, Phase 3
42 Antidepressive Agents Phase 3
43 Psychotropic Drugs Phase 3
44 Antidepressive Agents, Tricyclic Phase 3
45 Antiparasitic Agents Phase 3
46 Antiprotozoal Agents Phase 3
47 Insulin, Globin Zinc Phase 3
48 insulin Phase 3
49 Vitamin B Complex Phase 3
50 Antidotes Phase 3

Interventional clinical trials:

(show top 50) (show all 142)
# Name Status NCT ID Phase Drugs
1 Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients. A Randomized Controlled Trial Unknown status NCT01853709 Phase 4 Polyethylene glycol (PEG);Bisacodyl
2 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
3 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
4 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT01225237 Phase 4 Ramosetron;Placebo
5 Endoscopic Detection of Small Bowel Dysplasia and Cancer in Patients With Jejuna or Ileal Crohn Disease : Prospective Study in a Cohort of High Risk Patients Completed NCT01180452 Phase 4
6 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial Completed NCT02010762 Phase 4 Vitamin D;Placebo
7 A Randomized Clinical Trial Comparing Standard and Invidualized Bowel Preparation for Colonoscopy Recruiting NCT03428724 Phase 4 Standard Preparation;Individualized Preparation
8 Continuous Ketamine Infusion Versus Placebo in the Treatment of Acute Post-Surgical Pain: A Randomized Trial Evaluating the Efficacy of Ketamine in Colorectal Surgery Withdrawn NCT02785003 Phase 4 Placebo;Ketamine;Acetaminophen;Opioid;Alvimopan
9 Randomised Study Comparing the Use of Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy Unknown status NCT03466632 Phase 3 Propofol;Dexmedetomidine
10 Evaluation of PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon Completed NCT00604162 Phase 3
11 Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Night Procedure Completed NCT00951587 Phase 3
12 Evaluation of PillCam™ Colon 2 in Visualization of the Colon Completed NCT01063231 Phase 3
13 A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK-1701TC Completed NCT03509220 Phase 3 PBK-1701TC;Standard oral preparation
14 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome Completed NCT01553747 Phase 3 Eluxadoline;Placebo
15 Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery Completed NCT02716285 Phase 3 Ileocolonic release peppermint oil;Placebo;Small intestinal release peppermint oil
16 Multicenter Trial of Functional Bowel Disorders Completed NCT00006157 Phase 3 Desipramine
17 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Completed NCT01008423 Phase 3 Budesonide;Placebo
18 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Completed NCT01008410 Phase 3 Budesonide;Placebo
19 A Prospective, Randomized, Single-blinded (Evaluator), 3-treatment Arm, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of CDFR0612 and CDFR0613 Completed NCT02304523 Phase 3 CDFR0612;CDFR0613;Coolprep Powder
20 A Phase I, Dose-Escalation, Pilot Study of Visilizumab in Patients With Severe Ulcerative Colitis That is Refractory to Corticosteroids Completed NCT00032305 Phase 2, Phase 3 Visilizumab
21 Phase III Study to Evaluate the Effect of 10% Metronidazole Ointment, Applied Topically Three Times a Day in and Around the Anus and the Change in Perianal Crohn's Disease Activity Completed NCT00509639 Phase 3 10% Metronidazole Ointment
22 Randomized Clinical Trial on the Efficacy of an Adapted Bowel Preparation for Diabetic Patients Undergoing a Colonoscopy. DIMEPREP Study Completed NCT02300779 Phase 3
23 Improvement of Tolerability for Bowel Preparation for Colonoscopy in Diabetic Patients. A Randomized Controlled Trial of Two Bowel Preparation Protocols Including 4 Liters PEG vs. 2 Liters PEG Plus Ascorbic Acid. iDIMEPREP Study. Completed NCT02297399 Phase 3 PEG-ascorbate 2L;PEG 4L
24 A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Recruiting NCT03464305 Phase 3 acetylsalicylic acid;Placebo
25 A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC). Active, not recruiting NCT02753127 Phase 3 Napabucasin;Fluorouracil;Leucovorin;Irinotecan;Bevacizumab
26 A Phase 3, Open Label, Multicenter Study to Assess the Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis Terminated NCT01349673 Phase 3 Budesonide Foam
27 A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of a 12-week Add-on Treatment With LT-02 vs. Placebo in Subjects With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine Terminated NCT02849951 Phase 3 LT-02;LT-02 Placebo
28 A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis Terminated NCT01016262 Phase 3 MAX-002;Placebo;Canasa®
29 Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer Unknown status NCT00201331 Phase 2 leucovorin+5-FU
30 A Randomized, Double Blind, Single Dose, Two Treatment, Two Period Crossover Pharmacokinetic Study Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®) in Healthy Volunteers Completed NCT02291445 Phase 2 Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule);Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)
31 A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea Completed NCT01130272 Phase 2 Eluxadoline;Placebo
32 Phase II Study of YM060 - Double-blind, Parallel-group Comparative Study in Patients (Female) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT01274000 Phase 2 YM060;placebo
33 Clinical Study to Test the Efficacy of Herbal Medicine in Relieving Symptoms and Change of Quality of Life of Patients With IBS Completed NCT00153751 Phase 2 Traditional Chinese Medicine;Holopon
34 A Phase 2 Study of GVAX Colon Vaccine (With Cyclophosphamide) and Pembrolizumab in Patients With Mismatch Repair-Proficient (MMR-p) Advanced Colorectal Cancer Completed NCT02981524 Phase 2 CY;Pembrolizumab
35 The Effect of Kyo-Dophilus 1.5 Billion on the Symptoms of Severe Irritable Bowel Syndrome Completed NCT01887834 Phase 1, Phase 2
36 Randomised, Controlled Trial of Intravenous Saline Pre-hydration in Patients Undergoing Outpatient Colonoscopy Completed NCT00308152 Phase 2 Infusion of 1 litre of normal saline before colonoscopy
37 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC Completed NCT02647866 Phase 2 KHK4083;Placebo
38 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRN 002 (Crofelemer) for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS) Completed NCT00101725 Phase 2 crofelemer
39 The Effect of Kyo-Dophilus 1.5 Billion on the Symptoms of Irritable Bowel Syndrome (IBS) Completed NCT01176227 Phase 1, Phase 2
40 Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors Completed NCT01177007 Phase 2
41 A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy Completed NCT01926444 Phase 2 GIC-1001
42 Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease Completed NCT02321280 Phase 1, Phase 2 Denosumab
43 Evaluation of the Effect of the Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Metastatic Colorectal Adenocarcinoma. Phase II Recruiting NCT03559543 Phase 2
44 An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type Patients With Metastatic Colorectal Carcinoma as 1st Therapy Recruiting NCT04080843 Phase 2 Anlotinib Hydrochloride;Capecitabine;Oxaliplatin
45 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
46 A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Recruiting NCT03093116 Phase 1, Phase 2 Oral repotrectinib (TPX-0005)
47 A Phase I/II Study of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers Active, not recruiting NCT03332498 Phase 1, Phase 2 Pembrolizumab;Ibrutinib
48 Phase I/II Study of Intravenous Ascorbic Acid in Combination With Irinotecan Versus Irinotecan Alone for Advanced Colorectal Cancer Terminated NCT01550510 Phase 1, Phase 2 Ascorbic Acid;Irinotecan
49 Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer Terminated NCT00838578 Phase 1, Phase 2 Irinotecan
50 A Phase 2 Study to Evaluate the Safety and Potential Efficacy of Clostridium Butyricum MIYAIRI 588 Strain (MIYA-BM Fine Granules) for the Prevention of Recurrent Clostridium Difficile Infections Withdrawn NCT01077245 Phase 2 MIYA-BM Fine Granules (CBM588);Placebo Fine Granules (without CBM588)

Search NIH Clinical Center for Colonic Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Scopolamine Hydrobromide

Cochrane evidence based reviews: colonic diseases

Genetic Tests for Colonic Disease

Anatomical Context for Colonic Disease

MalaCards organs/tissues related to Colonic Disease:

Colon, Testes, Kidney, Small Intestine, Liver, Brain, Thyroid

Publications for Colonic Disease

Articles related to Colonic Disease:

(show top 50) (show all 1185)
# Title Authors PMID Year
Robotic Colorectal Surgery. 42
32169183 2020
What are the Particularities of Colorectal Surgery in Cirrhotic Patients. 42
32369718 2020
Checkpoint Inhibitor-Induced Colitis. 42
31922959 2020
Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohn's disease in an Australian population. 54 61
18213697 2008
Chemoprevention in familial adenomatous polyposis: past, present and future. 61
32507936 2020
pH-dependent ileocolonic drug delivery, part I: in vitro and clinical evaluation of novel systems. 61
32554060 2020
Inulin as a delivery vehicle for targeting colon-specific cancer. 61
32459607 2020
Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. 61
32476236 2020
Post-Translational Modifications of Transcription Factors Harnessing the Etiology and Pathophysiology in Colonic Diseases. 61
32369982 2020
A case report of iatrogenic gas gangrene post colonoscopy successfully treated with conservative management- is surgery always necessary? 61
32460761 2020
The surprise pathology-Primary squamous cell carcinoma of the colon-A case report. 61
32516701 2020
Trans-stomal single-port laparoscopic Hartmann's reversal is an efficacious and efficient procedure: a case-controlled study. 61
32200457 2020
Ileal or Colonic Histologic Activity is Not Associated With Clinical Relapse in Patients With Crohn's Disease in Endoscopic Remission. 61
32360823 2020
In vitro release kinetics of graft matrices from Lannea coromandelica (Houtt) gum for treatment of colonic diseases by 5-ASA. 61
32027894 2020
Is fecal calprotectin an accurate marker in the management of Crohn's disease? 61
31795013 2020
Update on SLC6A14 in lung and gastrointestinal physiology and physiopathology: focus on cystic fibrosis. 61
32166393 2020
High-Fat Diet Propelled AOM/DSS-Induced Colitis-Associated Colon Cancer Alleviated by Administration of Aster glehni via STAT3 Signaling Pathway. 61
32024285 2020
Proteomics Highlights Common and Distinct Pathophysiological Processes Associated with Ileal and Colonic Ulcers in Crohn's Disease. 61
31282946 2020
The xenobiotic sensing pregnane X receptor regulates tissue damage and inflammation triggered by C difficile toxins. 61
31907988 2020
Observer agreement for small bowel ultrasound in Crohn's disease: results from the METRIC trial. 61
32037466 2020
A comparative study of hyperelastic constitutive models for colonic tissue fitted to multiaxial experimental testing. 61
31877516 2020
Korean Children and Adolescents with Crohn's Disease Are More Likely to Present with Perianal Fistulizing Disease at Diagnosis Compared to Their European Counterparts. 61
31988875 2020
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. 61
31644790 2020
Management of the Elderly Inflammatory Bowel Disease Patient. 61
31935714 2020
Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements. 61
31952340 2020
Distinct Disease Phenotype of Ulcerative Colitis in Patients With Coincident Primary Sclerosing Cholangitis: Evidence From a Large Retrospective Study With Matched Cohorts. 61
31725582 2019
Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases? 61
31009791 2019
The Incidence of Sexual Dysfunction in Patients With Irritable Bowel Syndrome. 61
31604682 2019
Improvement of Oxazolone-Induced Ulcerative Colitis in Rats Using Andrographolide. 61
31878303 2019
Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. 61
30914450 2019
[New frontiers in the establishment and application of colonic organoids]. 61
31770844 2019
Upper Gastrointestinal Disease Influences the Occurrence of Inflammatory Bowel Disease. 61
31776861 2019
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. 61
31567640 2019
Relationship between Barrett's esophagus and colonic diseases: a role for colonoscopy in Barrett's surveillance. 61
31240437 2019
Intracorporeal versus extracorporeal anastomosis in minimally invasive right colectomy: an updated systematic review and meta-analysis. 61
31646396 2019
Expression of receptor interacting protein 3 and mixed lineage kinase domain-like protein-key proteins in necroptosis is upregulated in ulcerative colitis. 61
31431023 2019
Relationship between Ulcerative Colitis and Rheumatoid Arthritis: A Review. 61
31720163 2019
Silk fibroin-based nanotherapeutics: application in the treatment of colonic diseases. 61
31290366 2019
An Orally Administrated Hyaluronan Functionalized Polymeric Hybrid Nanoparticle System for Colon-Specific Drug Delivery. 61
31480704 2019
Fermentation characteristics of resistant starch, arabinoxylan, and β-glucan and their effects on the gut microbial ecology of pigs: A review. 61
31528722 2019
Diffusion-weighted magnetic resonance for assessing fibrosis in Crohn's disease. 61
31392397 2019
Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms. 61
31465327 2019
Natural history of children with mild Crohn's disease. 61
31435176 2019
The Role of Laparoscopic, Robotic, and Open Surgery in Uncomplicated and Complicated Inflammatory Bowel Disease. 61
31078253 2019
Small bowel capsule endoscopy in ulcerative colitis: the capcolitis study: a prospective observational study. 61
31082999 2019
Microscopic/"Backwash" Ileitis and Its Association With Colonic Disease in New Onset Pediatric Ulcerative Colitis. 61
31124991 2019
A 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort. 61
30576474 2019
The association between the increased performance of laparoscopic colon surgery and a reduced risk of surgical site infection. 61
30684051 2019
Group IID, IIE, IIF and III secreted phospholipase A2s. 61
30905347 2019
Antibiotic-resistant hypervirulent Klebsiella pneumoniae causing community- acquired liver abscess: an emerging disease. 61
31198568 2019

Variations for Colonic Disease

Expression for Colonic Disease

Search GEO for disease gene expression data for Colonic Disease.

Pathways for Colonic Disease

Pathways related to Colonic Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
2 11.96 STAT3 MIR9-1 MIR31 MIR30A MIR21 MIR200A
3 11.36 MIR30A MIR18A MIR17
4 10.91 STAT3 MIR9-1 MIR199A1
5 10.7 NOD2 ESR1 APC
6 10.48 MIR199A1 MIR145
7 10.44 STAT3 ESR1

GO Terms for Colonic Disease

Cellular components related to Colonic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 MIR31 MIR30A MIR21 MIR199A1 MIR18A MIR17
2 extracellular vesicle GO:1903561 9.26 MIR30A MIR21 MIR17 MIR125A

Biological processes related to Colonic Disease according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.03 STAT3 MIR30A MIR21 MIR155 MIR125A
2 negative regulation of gene expression GO:0010629 9.95 MIR21 MIR17 MIR155 MIR125A ESR1
3 positive regulation of cell migration GO:0030335 9.94 STAT3 MIR30A MIR21 APC
4 positive regulation of protein kinase B signaling GO:0051897 9.89 MIR21 MIR199A1 MIR143 ESR1
5 negative regulation of angiogenesis GO:0016525 9.84 MIR21 MIR145 MIR143 MIR125A
6 positive regulation of fibroblast proliferation GO:0048146 9.76 MIR17 MIR155 ESR1
7 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.73 MIR21 MIR199A1 MIR145
8 positive regulation of blood vessel endothelial cell migration GO:0043536 9.73 MIR31 MIR30A MIR200A MIR143
9 negative regulation of vascular endothelial growth factor production GO:1904046 9.69 MIR199A1 MIR17 MIR125A
10 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.66 MIR17 MIR155
11 positive regulation of connective tissue replacement GO:1905205 9.65 MIR199A1 MIR155
12 interleukin-15-mediated signaling pathway GO:0035723 9.65 STAT3 JAK1
13 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.65 MIR21 MIR125A
14 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.65 MIR199A1 MIR17 MIR155
15 interleukin-35-mediated signaling pathway GO:0070757 9.64 STAT3 JAK1
16 interleukin-27-mediated signaling pathway GO:0070106 9.63 STAT3 JAK1
17 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.63 MIR199A1 MIR17 MIR155
18 positive regulation of angiogenesis GO:0045766 9.63 STAT3 MIR31 MIR30A MIR21 MIR199A1 MIR143
19 angiotensin-activated signaling pathway GO:0038166 9.62 MIR145 MIR143
20 interleukin-9-mediated signaling pathway GO:0038113 9.62 STAT3 JAK1
21 positive regulation of sprouting angiogenesis GO:1903672 9.62 MIR31 MIR155 MIR125A JAK1
22 negative regulation of regulatory T cell differentiation GO:0045590 9.61 MIR21 MIR155
23 interleukin-21-mediated signaling pathway GO:0038114 9.61 STAT3 JAK1
24 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.6 MIR21 MIR17
25 aorta smooth muscle tissue morphogenesis GO:0060414 9.58 MIR145 MIR143
26 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.58 MIR31 MIR155 MIR125A
27 regulation of phenotypic switching GO:1900239 9.57 MIR145 MIR143
28 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.56 STAT3 NOD2 MIR21 MIR17
29 miRNA mediated inhibition of translation GO:0035278 9.56 STAT3 MIR9-1 MIR31 MIR30A MIR21 MIR17
30 positive regulation of metalloendopeptidase activity GO:1904685 9.54 STAT3 MIR21 MIR17
31 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.52 MIR17 MIR143
32 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.49 MIR145 MIR143
33 gene silencing by miRNA GO:0035195 9.4 MIR9-1 MIR31 MIR30A MIR21 MIR200A MIR199A1

Molecular functions related to Colonic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.4 MIR9-1 MIR31 MIR30A MIR21 MIR200A MIR199A1
2 CCR5 chemokine receptor binding GO:0031730 8.96 STAT3 JAK1

Sources for Colonic Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....